These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 1528325)

  • 21. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.
    Waud WR
    Cancer Res; 1987 Dec; 47(24 Pt 1):6549-55. PubMed ID: 3677093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
    Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
    Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
    Holzer AK; Manorek GH; Howell SB
    Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
    Teicher BA; Holden SA; Kelley MJ; Shea TC; Cucchi CA; Rosowsky A; Henner WD; Frei E
    Cancer Res; 1987 Jan; 47(2):388-93. PubMed ID: 3539321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake.
    Shen DW; Goldenberg S; Pastan I; Gottesman MM
    J Cell Physiol; 2000 Apr; 183(1):108-16. PubMed ID: 10699972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
    Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
    Anticancer Drug Des; 1994 Dec; 9(6):495-509. PubMed ID: 7880375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G; Howell SB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacological approach to the platinum compounds].
    Sasaki Y
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
    Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
    Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P; Loh SY; Kelland LR; Harrap KR
    Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Murine leukemia L1210 cell lines with different patterns of resistance to platinum coordination complexes.
    Eastman A; Illenye S
    Cancer Treat Rep; 1984 Sep; 68(9):1189-90. PubMed ID: 6541096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No correlation between GSH levels in human cancer cell lines and the cell growth inhibitory activities of platinum diamine complexes.
    Boubakari ; Bracht K; Neumann C; Grünert R; Bednarski PJ
    Arch Pharm (Weinheim); 2004 Dec; 337(12):668-71. PubMed ID: 15614830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
    Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells.
    Kido Y; Khokhar AR; Siddik ZH
    Biochem Pharmacol; 1994 Apr; 47(9):1635-42. PubMed ID: 8185678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells.
    Richon VM; Schulte N; Eastman A
    Cancer Res; 1987 Apr; 47(8):2056-61. PubMed ID: 3828995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.